期刊
CANCER JOURNAL
卷 28, 期 4, 页码 301-309出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/PPO.0000000000000607
关键词
Adoptive cell therapy; oncodrivers; tumor associated antigens; TIL therapy; engineered TCR therapy; CAR therapy; DC therapy; NK therapy
类别
资金
- Bankhead-Coley
This review discusses the standard treatments for metastatic breast cancer, focusing on the rationale for targeted therapy and the significance of immune response in immunotherapeutic studies. It provides an overview of various types of adoptive cell therapy in breast cancer and summarizes the clinical data regarding their use. Future adoptive cell therapy approaches for curing breast cancer are also proposed.
Metastatic breast cancer (BC) is an aggressive form of cancer and is an absolute challenge to treat. This review discusses the standard treatments available for metastatic BC. It further highlights the rationale for targeting oncodrivers, tumor-associated antigens, and neoantigens in BC. Explaining the significance of immune response in successful immunotherapeutic studies, it draws attention towards how adoptive cell therapy can be a useful immunotherapeutic tool. We focus on adoptive cell therapy in BC covering tumor-infiltrating lymphocyte therapy, engineered T cell receptor therapy, chimeric antigen receptor therapy, dendritic cell therapy and natural killer cell therapy. In this work, we aim to provide an overview of clinical data regarding the use of cellular immunotherapies in BC. Eventually, we conclude by proposing future adoptive cell therapy approaches, which can be used to cure BC.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据